Chapman et al. [23] showed by ELISA in 2007 that serum anti-MUC1 AAbs were present in 19/94 (20.2%) patients with newly diagnosed breast carcinoma and 10/40 (25%) patients with ductal carcinoma in situ. This evidence concerns the gene MUC1 and breast carcinoma.